Skip to main content
Novo NordiskIn development

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat

Source: Autobound Signal API · 93 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk is evaluating the effect of its once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis in its ongoing phase 3 ESSENCE trial, with results from the second part expected in 2029.

Source

Article excerpt

Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy® (injectable semaglutide 7.2 and 2.4 mg) treatment. Bagsværd, Denmark, 1 October 2026 – Novo Nordisk today presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. 1 Change in percentage of liver fat, determined by magnetic resonance imaging (MRI), showed that mean liver fat in the group taking semaglutide declined from 8.8% at baseline to 3.1% at week 72. In addition, the analysis showed that 26 participants entered the trials with liver fat above 5% and 88.5% of them – 23 participants – reached the below-5% threshold by week 72, bringing their liver fat to normal levels. The findings are presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. 1 “This analysis showed that semaglutide reduced liver fat and was linked to better overall liver health in adults with obesity,” said Eric Lawitz, MD, Texas Liver Institute and University of Texas Health San Antonio. “These findings suggest semaglutide may help address liver disease early – before it becomes a serious health problem – that could harm the heart, kidney...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted from this sentence

ESSENCE is an ongoing phase 3 trial evaluating the effect of once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis (stage F2 or F3).

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
semaglutide 2.4 mg
Location
Bagsværd, Capital Region of Denmark, Denmark

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • general technology

Extraction

Confidence
80%
Detected
Oct 1, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/f155e8c0-57a1-b649-8c30-35ac2349a1c0 returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "f155e8c0-57a1-b649-8c30-35ac2349a1c0",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-01T10:45:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/01/3372708/0/en/novo-s-wegovy-semaglutide-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-easd2026.html",
    "title": "Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026",
    "excerpt": "Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy® (injectable semaglutide 7.2 and 2.4 mg) treatment. Bagsværd, Denmark, 1 October 2026 – Novo Nordisk today presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. 1 Change in percentage of liver fat, determined by magnetic resonance imaging (MRI), showed that mean liver fat in the group taking semaglutide declined from 8.8% at baseline to 3.1% at week 72. In addition, the analysis showed that 26 participants entered the trials with liver fat above 5% and 88.5% of them – 23 participants – reached the below-5% threshold by week 72, bringing their liver fat to normal levels. The findings are presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy. 1 “This analysis showed that semaglutide reduced liver fat and was linked to better overall liver health in adults with obesity,” said Eric Lawitz, MD, Texas Liver Institute and University of Texas Health San Antonio. “These findings suggest semaglutide may help address liver disease early – before it becomes a serious health problem – that could harm the heart, kidney, liver...",
    "product": "semaglutide 2.4 mg",
    "summary": "Novo Nordisk is evaluating the effect of its once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis in its ongoing phase 3 ESSENCE trial, with results from the second part expected in 2029.",
    "location": "Bagsværd, Denmark",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f87e6f85-3e50-4571-b9e5-8f683431f855",
    "confidence": 0.8,
    "product_data": {
      "name": "semaglutide 2.4 mg",
      "full_text": "once-weekly injectable semaglutide 2.4 mg",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-10-01T10:45:00Z",
    "location_data": [
      {
        "city": "Bagsværd",
        "state": "Capital Region of Denmark",
        "region": "Northern Europe",
        "country": "Denmark",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "ESSENCE is an ongoing phase 3 trial evaluating the effect of once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis (stage F2 or F3)."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.